Effects of different doses of atorvastatin on serum lipids,big-ET,hs-CRP and PAP in hyperlipidemia patients with chronic cor pulmonale

Objective To investigate the safety and therapeutic effect of different doses of atorvastatin on lipid-lowering,endothelial function,high-sensitivity C-reactive protein ( hs-CRP) and pulmonary artery pressure ( PAP) in hyperlipidemia patients with chronic cor pulmonale. Methods 100 hyperlipidemia patients with chronic cor pulmonale were randomly divided into two groups. The patients in disorder lipidemia group were given atorvastatin 10mg qd or 20 mg qd for 24 weeks. The levels of TC,TG,LDL-C,HDL-C,big-ET and hs-CRP,PAP were determined in disorder lipidemia groups 24 hours after pretreatment or treatment. Results TC and LDL-C were decreased significantly( P 0. 05) in both groups after 24 weeks,but the decrease in atorvastatin 20mg qd group was more obvious. Big-ET in atorvastatin 20mg qd group was reduced from ( 0. 69 ± 0. 26 ) pmol/L before treatment to ( 0. 43 ± 0. 07) pmol/L after 24-week treatment,which also was significantly lower than that of atorvastatin 10mg qd group( 0. 51 ± 0. 08) pmol/L ( P 0. 05). hs-CRP in atorvastatin 20mg qd group was decreased from( 7. 1 ± 2. 1) mg/L before treatment to( 3. 8 ± 0. 4) mg/L after 24-week treatment,which was significantly lower than that of atorvastatin 10mg qd group( 4. 4 ± 0. 6) mg/L( P 0. 05). PAP in atorvastatin 20mg qd group was reduced from( 54 ± 18) mmHg before treatment to( 30 ± 7) mmHg after 24-week treatment,which was significantly lower than that of atorvastatin 10mg qd group( 42 ± 8) mmHg( P 0. 05). Conclusion The atorvanstain can reduce obviously blood lipid,hs-CRP and PAP,and can improve endothelial function. The administration of atorvanstain 20mg qd is safe,which is effective in controlling blood lipid,decreasing hs-CRP,PAP and improving endothelial function.